Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for first quarter ended March 31, 2022 before the market opens on May 4, 2022, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.
HOLLISTON, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- Harvard Bioscience Inc. (Nasdaq: HBIO) will announce its financial results for first quarter ended March 31, 2022 before the market opens on May 4, 2022, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.
You can access the live conference call by dialing the following phone numbers: toll-free 1 (877) 303-7611 or international 1 (970) 315-0445 and referencing the conference ID #6757353.
The conference call will be simultaneously webcast and can be accessed through the Harvard Bioscience website. To listen to the webcast, go to http://investor.harvardbioscience.com/ – Events & Presentations.
Financial information presented on the call, including the earnings release and a related slide presentation, will be available on the Investor Relations section of Harvard Bioscience’s website.
About Harvard Bioscience
Harvard Bioscience is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. Our customers range from renowned academic institutions and government laboratories, to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in North America, Europe and China, we sell through a combination of direct and distribution channels to customers around the world.
For more information, please visit our website at www.harvardbioscience.com.
Investor Contact
Michael Rossi
Chief Financial Officer
(508) 893-8999
mrossi@harvardbioscience.com
